EXEL Exelixis, Inc. - Common Stock
$54,24
Harga · Agu 19, 2026
Fundamental per Agu 5, 2026
Rentang 52M
$34–$58
86% of range
Peringkat Analis
HOLD
26 analysts
Target Harga
$53
P/E (TTM)
18.9
ROE
37.3%
Margin Laba Bersih
33.7%
Tentang Exelixis, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Baca selengkapnya
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
History
Exelixis was founded in 1994; the scientific founders were Spyridon Artavanis–Tsakonas, at Yale at that time, and Corey Goodman and Gerry Rubin who were then at the University of California, Berkeley. George Scangos joined the company as CEO in 1996. The business plan was to use model organisms (fruit flies, nematodes, and zebrafish) and functional genomics to identify pathways and biological targets that could be exploited in the fields of agriculture and medicine. It eventually set up a subsidiary, Exelixis Plant Sciences, for the agricultural work.
By 2000, Exelixis had left the radical exploratory phase behind and became focused on drug discovery and had a chemical library of 4 million compounds. The company went public that year, after withdrawing its offering the week before; it raised $118 million in a down market.
In 2002, the company signed a broad alliance with GSK to discover new drugs in the fields of cancer, inflammatory diseases, and vascular conditions; GSK paid it $30 million in cash, bought $14 million in stock at twice the market rate, and committed to providing Exelixis with $90 million in research funding; it also offered loan financing of up to $85 million.
By 2002, the company had limited its internal efforts to cancer, and had settled its strategy on discovering and developing drugs that could inhibit targeted small sets of tyrosine kinases that are needed for cancer formation, growth, and metastasis. The sets of TKs had been identified by means of its prior functional genomics work. This approach was controversial at the time; most companies try to selectively target just one protein in their discovery efforts.
In 2006, Exelixis partnered with Daiichi Sankyo on compounds that targeted mineralocorticoid receptors; esaxerenone was part of this collaboration. In 2007, the company partnered its MEK inhibitor program with Genentech; cobimetinib (at that time XL-518) was part of this collaboration. Exelixis had filed an IND on XL-518 prior to the partnership, committed to funding and running the Phase I trial, and retained rights to co-market it in the US.
In 2008, the company partnered its lead cancer drug candidate, XL-184 (which would become called cabozantinib) and another cancer candidate, XL-281, with Bristol Myers Squibb; BMS returned the rights to XL-184 to Exelixis in 2010 and returned the rights to other drug candidate in 2011.
In 2010, Scangos departed as CEO to take over at Biogen and the company appointed Michael M. Morrissey as president and CEO; Morrissey had joined the company in 2000 as Vice President of Discovery Research. At that time the company had eight drugs in clinical trials.
Exelixis' first drug approval came in 2012, when cabozantinib was approved for medullary thyroid cancer, an orphan indication. It was approved in Europe in 2014.
Exelixis invested heavily in exploring cabozantinib in other cancers, betting the future of the company on the drug. In 2014 the drug failed a Phase III trial in prostate cancer, and the company laid off 70% of its employees.
In 2015, Genentech and Exelixis won FDA approval for cobimetinib for certain forms of melanoma.
In March 2016, Exelixis licensed to Ipsen worldwide rights (outside the US, Canada, and Japan) to market cabozantinib.
In April 2016, the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer and the same was approved in Europe in October of that year.
In December 2017, the FDA granted approval for the use of cabozantinib for first line treatment of kidney cancer and in 2018 approval for first-line treatment was approved in Europe.
Finance
Pricing
Cabometyx (cabozantinib)
In 2023, the Institute for Clinical and Economic Review (ICER) identified Cabometyx (cabozantinib) as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Cabometyx's wholesale acquisition cost rose by 7.5%, leading to an additional $86 million in costs to U.S. payers.
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
EXEL Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$54.24
Kapitalisasi Pasar
$13.76B
P/E (TTM)
18.9
EPS (TTM)
$2.78
Pendapatan (TTM)
$2.32B
Imbal Hasil Dividen
—
ROE
37.3%
D/E Utang/Ekuitas
—
Rentang 52M
$34 – $58
EXEL Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
$2.32B
2016-12-31
→
2026-01-02
EPS
$2.78
2017-12-29
→
2026-01-02
Arus Kas Bebas
$876M
2017-12-29
→
2026-01-02
Margin
33.7%
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
EXEL
Median Rekan
P/E (TTM)
18.9
28.5
P/S (TTM)
5.9
20.1
P/B
6.4
12.9
Price / FCF (Harga / FCF)
15.7
—
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
EXEL
Median Rekan
Operating Margin (Margin Operasi)
37.6%
—
Net Profit Margin (Margin Laba Bersih)
33.7%
-48.4%
ROA
27.0%
-28.4%
ROE
37.3%
-49.2%
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
EXEL
Median Rekan
Current Ratio (Rasio Lancar)
3.6
5.0
Quick Ratio (Rasio Cepat)
3.3
—
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
EXEL
Median Rekan
Revenue YoY (Pendapatan YoY)
7.0%
—
Revenue CAGR 3Y (CAGR Pendapatan 3T)
12.9%
—
Revenue CAGR 5Y (CAGR Pendapatan 5T)
18.6%
—
EPS YoY
58.0%
—
Net Income YoY (Laba Bersih YoY)
50.1%
—
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
EXEL
Median Rekan
EXEL Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
BELI
26 analis
- Beli Kuat 5 19,2%
- Beli 8 30,8%
- Tahan 12 46,2%
- Jual 1 3,8%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
16 analis · 2026-08-13
Median
$52.00
Sekarang
$54.24
Rendah
$41.00
Tinggi
$66.00
Target median
$52.00
-4,1%
Target rata-rata
$52.94
-2,4%
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
0.08%
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $0.82 | $0.80 | 0.02% |
| 31 Maret 2026 | $0.79 | $0.72 | 0.07% |
| 31 Des. 2025 | $0.88 | $0.82 | 0.06% |
| 30 Sep. 2025 | $0.69 | $0.63 | 0.06% |
| 30 Juni 2025 | $0.65 | $0.57 | 0.08% |
| 31 Maret 2025 | $0.55 | $0.37 | 0.18% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 16
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | $191M | $37M | |
| Cost of Revenue | $84M | $76M | $73M | $58M | $53M | $36M | $33M | $26M | $15M | $7M | $4M | |
| R&D Expense | $825M | $910M | $1.04B | $892M | $694M | $548M | $337M | $182M | $112M | $96M | $96M | |
| SG&A Expense | $519M | $492M | $543M | $460M | $402M | $293M | $228M | $206M | $159M | $116M | $57M | |
| Operating Expenses | $1.45B | $1.56B | $1.66B | $1.41B | $1.15B | $877M | $598M | $415M | $287M | $220M | $159M | |
| Operating Income | $872M | $605M | $171M | $201M | $287M | $110M | $369M | $439M | $166M | $-28M | $-121M | |
| Interest Expense | · | · | · | · | · | · | $0 | $0 | $9M | $33M | $41M | |
| Other Non-op | $-198.0K | $-133.0K | $93.0K | $-197.0K | $-184.0K | $912.0K | $680.0K | $397.0K | $-4M | $5M | $-381.0K | |
| Pretax Income | · | · | · | · | · | $131M | $398M | $452M | $159M | $-70M | $-162M | |
| Income Tax | $159M | $160M | $50M | $52M | $63M | $19M | $77M | $-238M | $4M | $0 | $55.0K | |
| Net Income | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | $-70M | $-162M | |
| EPS (Basic) | $2.88 | $1.80 | $0.65 | $0.57 | $0.73 | $0.36 | $1.06 | $2.32 | $0.52 | · | $-0.77 | |
| EPS (Diluted) | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | · | $-0.77 | |
| Shares (Basic) | 271,567,000 | 290,030,000 | 318,151,000 | 321,526,000 | 314,884,000 | 308,271,000 | 302,584,000 | 297,892,000 | 293,588,000 | · | 209,227,000 | |
| Shares (Diluted) | 281,863,000 | 296,132,000 | 321,464,000 | 324,556,000 | 322,359,000 | 318,001,000 | 315,009,000 | 312,803,000 | 312,003,000 | · | 209,227,000 | |
| EBITDA | $901M | $633M | $197M | $222M | $300M | $119M | $378M | $444M | $167M | · | · |
Neraca 27
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $482M | $217M | $263M | $501M | $647M | $319M | $267M | $315M | $183M | $152M | $142M | |
| Short-term Investments | $577M | $894M | $732M | $807M | $820M | $887M | $586M | $379M | $205M | $268M | · | |
| Receivables | $287M | $265M | $237M | $215M | $283M | $161M | $119M | $163M | $77M | $40M | · | |
| Inventory | $22M | $22M | $17M | $33M | $27M | $21M | $13M | $10M | $7M | $3M | · | |
| Prepaid Expense | $76M | $68M | $68M | $62M | $58M | $57M | $27M | $31M | $9M | $5M | · | |
| Current Assets | $1.44B | $1.47B | $1.32B | $1.62B | $1.83B | $1.45B | $1.01B | $897M | $485M | $469M | · | |
| PP&E (Net) | $99M | $119M | $129M | $111M | $104M | $67M | $49M | $51M | $26M | $2M | · | |
| PP&E (Gross) | $231M | $220M | $209M | $171M | $145M | $102M | $74M | $68M | $49M | $27M | · | |
| Accum. Depreciation | $132M | $101M | $80M | $61M | $41M | $35M | $26M | $17M | $23M | $25M | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | |
| Other Non-current Assets | · | · | · | · | $131M | $73M | $53M | $8M | $12M | $1M | · | |
| Total Assets | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Accounts Payable | $30M | $38M | $34M | $33M | $24M | $24M | $12M | $11M | $10M | $7M | · | |
| Short-term Debt | · | · | · | · | · | · | · | · | $0 | $80M | · | |
| Current Liabilities | $406M | $404M | $394M | $324M | $338M | $205M | $143M | $105M | $115M | $269M | · | |
| Capital Leases | $173M | $191M | $190M | $190M | $51M | $49M | $48M | $12M | $15M | · | · | |
| Other Non-current Liabilities | $104M | $109M | $94M | $69M | $8M | $721.0K | $2M | $1M | $2M | $541.0K | · | |
| Total Liabilities | $683M | $703M | $678M | $583M | $406M | $258M | $200M | $135M | $370M | $506M | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | $0 | $189M | · | |
| Total Debt | · | · | · | · | · | · | · | · | $0 | · | · | |
| Common Stock | $262.0K | $282.0K | $303.0K | $324.0K | $319.0K | $312.0K | $305.0K | $300.0K | $296.0K | $290.0K | · | |
| Paid-in Capital | $2.23B | $2.34B | $2.44B | $2.54B | $2.43B | $2.32B | $2.24B | $2.17B | $2.11B | $2.07B | · | |
| Retained Earnings | $-77M | $-99M | $-173M | $-34M | $-217M | $-448M | $-559M | $-880M | $-1.83B | $-1.98B | · | |
| AOCI | $3M | $-1M | $-4M | $-15M | $-758.0K | $4M | $3M | $-701.0K | $-347.0K | $-416.0K | · | |
| Stockholders' Equity | $2.16B | $2.24B | $2.26B | $2.49B | $2.21B | $1.88B | $1.69B | $1.29B | $285M | $89M | $-141M | |
| Liabilities + Equity | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Shares Outstanding | 262,483,000 | 281,732,000 | 302,793,000 | 323,951,000 | 318,842,000 | 311,627,000 | 304,831,000 | 299,876,000 | 296,209,000 | 289,923,798 | 227,960,943 |
Arus Kas 17
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $29M | $29M | $26M | $21M | $14M | $9M | $8M | $5M | $1M | $1M | $1M | |
| Stock-based Comp | $113M | $94M | $106M | $108M | $120M | $105M | $57M | $41M | $24M | $23M | $22M | |
| Deferred Tax | $126M | $-59M | $-133M | $-60M | $47M | $15M | $71M | $-244M | $0 | $0 | $0 | |
| Restructuring | $21M | $34M | $0 | $0 | · | · | · | $0 | $-32.0K | $63M | $1M | |
| Other Non-cash | $-167M | $116M | $127M | $112M | $-10M | $-32M | $70M | $-76M | $-14M | · | · | |
| Operating Cash Flow | $884M | $700M | $333M | $363M | $401M | $209M | $527M | $416M | $166M | $206M | $-141M | |
| CapEx | $8M | $28M | $40M | $28M | $54M | $30M | $13M | $33M | $21M | $2M | $447.0K | |
| Investing Cash Flow | $350M | $-117M | $-27M | $-524M | $-43M | $-131M | $-587M | $-298M | $37M | $-216M | $50M | |
| Net Debt Issued | · | · | · | · | · | · | $0 | $0 | $-186M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | $0 | $146M | |
| Stock Repurchased | $948M | $652M | $550M | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | $-948M | $-652M | $-550M | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $-970M | $-629M | $-546M | $586.0K | $-15M | $-25M | $13M | $10M | $-170M | $20M | $152M | |
| Net Change in Cash | $265M | $-46M | $-240M | $-161M | $343M | $53M | $-48M | $128M | $32M | $10M | $61M | |
| Taxes Paid | $155M | $170M | $186M | $128M | $13M | $4M | $8M | $11M | $538.0K | · | · | |
| Free Cash Flow | $876M | $672M | $293M | $335M | $337M | $179M | $514M | $382M | $144M | · | · | |
| Levered FCF | · | · | · | · | · | · | $514M | $382M | $136M | · | · |
Profitabilitas 7
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | · | · | |
| Net Margin | 33.7% | 24.0% | 11.3% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | · | · | |
| Pretax Margin | · | · | · | · | · | 13.2% | 41.1% | 52.9% | 35.0% | · | · | |
| EBITDA Margin | 38.8% | 29.2% | 10.7% | 13.8% | 20.9% | 12.1% | 39.0% | 52.0% | 36.9% | · | · | |
| ROA | 27.0% | 17.7% | 6.9% | 6.4% | 9.7% | 5.6% | 19.4% | 66.4% | 24.7% | · | · | |
| ROE | 37.3% | 23.1% | 9.0% | 7.3% | 10.7% | 6.0% | 19.5% | 62.6% | 82.4% | · | · | |
| ROIC | · | · | · | · | · | 5.0% | 17.7% | 52.0% | 56.6% | · | · |
Likuiditas & Solvabilitas 4
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 | 7.1 | 7.1 | 8.5 | 4.2 | · | · | |
| Quick Ratio | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 | 6.7 | 6.8 | 8.1 | 4.1 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 19.1 | · | · |
Efisiensi 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.8 | 0.7 | · | · | |
| Inventory Turnover | 3.8 | 3.8 | 2.9 | 1.9 | 2.2 | 2.1 | 2.9 | 3.2 | 3.0 | · | · | |
| Receivables Turnover | 8.4 | 8.6 | 8.1 | 6.5 | 6.5 | 7.1 | 6.9 | 9.8 | 7.4 | · | · |
Tingkat Pertumbuhan 9
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.0% | 18.5% | 13.6% | 12.3% | 45.3% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.9% | 14.8% | 22.8% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 18.6% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 58.0% | 170.8% | 16.1% | -22.2% | 105.7% | · | · | · | · | · | · | |
| EPS CAGR 3Y | 70.6% | 34.7% | 22.9% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 51.3% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 50.1% | 150.9% | 14.0% | -21.1% | 106.7% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 62.5% | 31.1% | 22.9% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 47.6% | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM) 14
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | · | $37M | |
| Net Income TTM | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | · | $-162M | |
| Market Cap | $11.44B | $9.57B | $7.26B | $5.20B | $5.83B | $6.25B | $5.19B | $5.83B | $9.00B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $8.62B | · | · | |
| P/E | 15.7 | 19.3 | 36.9 | 28.6 | 25.4 | 57.3 | 16.7 | 8.8 | 62.0 | · | -7.3 | |
| P/S | 4.9 | 4.4 | 4.0 | 3.2 | 4.1 | 6.3 | 5.4 | 6.8 | 19.9 | · | · | |
| P/B | 5.3 | 4.3 | 3.2 | 2.1 | 2.6 | 3.3 | 3.1 | 4.5 | 31.6 | · | · | |
| P / Tangible Book | 5.5 | 4.4 | 3.3 | 2.1 | 2.7 | 3.4 | · | · | · | · | · | |
| P / Cash Flow | 12.9 | 13.7 | 21.8 | 14.3 | 14.5 | 29.9 | 9.8 | 14.0 | 54.4 | · | · | |
| P / FCF | 13.1 | 14.3 | 24.8 | 15.5 | 17.3 | 35.0 | 10.1 | 15.2 | 62.3 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | 51.6 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | 59.6 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 19.0 | · | · | |
| Earnings Yield | 6.4% | 5.2% | 2.7% | 3.5% | 3.9% | 1.7% | 6.0% | 11.4% | 1.6% | · | -13.7% |
Laporan Laba Rugi 14
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $629M | $611M | $718M | $598M | $568M | $555M | $818M | $540M | $637M | $425M | $480M | $472M | $470M | $409M | $424M | $412M | |
| Cost of Revenue | $21M | $20M | $27M | $19M | $19M | $19M | $25M | $17M | $18M | $21M | $22M | $19M | $18M | $14M | $16M | $15M | |
| R&D Expense | $212M | $200M | $164M | $199M | $200M | $212M | $111M | $223M | $211M | $228M | $245M | $333M | $233M | $234M | $337M | $199M | |
| SG&A Expense | $148M | $140M | $161M | $124M | $135M | $137M | $81M | $112M | $132M | $114M | $131M | $138M | $142M | $131M | $119M | $115M | |
| Operating Expenses | $380M | $359M | $287M | $361M | $355M | $369M | $303M | $403M | $361M | $396M | $398M | $490M | $392M | $380M | $472M | $329M | |
| Operating Income | $248M | $251M | $431M | $237M | $214M | $187M | $516M | $136M | $276M | $29M | $82M | $-18M | $78M | $29M | $-48M | $83M | |
| Other Non-op | $54.0K | $219.0K | $207.0K | $-49.0K | $50.0K | $-245.0K | $-363.0K | $-29.0K | $-287.0K | $-89.0K | $-137.0K | $289.0K | $-5.0K | $-54.0K | $-337.0K | $-69.0K | |
| Income Tax | $51M | $57M | $43M | $59M | $46M | $46M | $128M | $37M | $67M | $12M | $18M | $5M | $19M | $8M | $-1M | $19M | |
| Net Income | $212M | $210M | $401M | $194M | $185M | $160M | $399M | $118M | $226M | $37M | $86M | $1M | $81M | $40M | $-30M | $73M | |
| EPS (Basic) | $0.85 | $0.81 | $1.57 | $0.72 | $0.68 | $0.57 | $1.43 | $0.41 | $0.78 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| EPS (Diluted) | $0.82 | $0.79 | $1.49 | $0.69 | $0.65 | $0.55 | $1.39 | $0.40 | $0.77 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| Shares (Basic) | 250,808,000 | 258,329,000 | -604,028,000 | 268,421,000 | 272,583,000 | 278,804,000 | -674,091,000 | 285,622,000 | 289,216,000 | 300,757,000 | -645,970,000 | 315,496,000 | 324,205,000 | 324,420,000 | 577,000 | 322,148,000 | |
| Shares (Diluted) | 259,675,000 | 267,322,000 | -609,119,000 | 278,535,000 | 284,393,000 | 288,177,000 | -676,699,000 | 291,478,000 | 293,974,000 | 305,530,000 | -651,367,000 | 319,247,000 | 327,305,000 | 326,279,000 | 136,000 | 325,066,000 | |
| EBITDA | $248M | $258M | · | $237M | $214M | $194M | · | $136M | $276M | $36M | · | $-18M | $78M | $36M | · | $83M |
Neraca 24
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $281M | $226M | $482M | $376M | $164M | $184M | $217M | $258M | $198M | $260M | · | $397M | $464M | $541M | · | $675M | |
| Short-term Investments | $558M | $551M | $577M | $612M | $627M | $848M | $894M | $931M | $804M | $704M | · | $707M | $802M | $773M | · | $872M | |
| Receivables | $322M | $329M | $287M | $310M | $292M | $282M | $265M | $270M | $397M | $241M | · | $248M | $233M | $234M | · | $215M | |
| Inventory | $29M | $27M | $22M | $27M | $23M | $25M | $22M | $21M | $21M | $21M | · | $25M | $29M | $30M | · | $27M | |
| Prepaid Expense | $60M | $76M | $76M | $77M | $74M | $59M | $68M | $70M | $58M | $67M | · | $67M | $62M | $61M | · | $53M | |
| Current Assets | $1.25B | $1.21B | $1.44B | $1.40B | $1.18B | $1.40B | $1.47B | $1.55B | $1.48B | $1.29B | · | $1.44B | $1.59B | $1.64B | · | $1.84B | |
| PP&E (Net) | $93M | $96M | $99M | $105M | $110M | $115M | $119M | $124M | $130M | $127M | · | $121M | $115M | $116M | · | $108M | |
| PP&E (Gross) | · | · | $231M | · | · | · | $220M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $132M | · | · | · | $101M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | $64M | $64M | $64M | · | $64M | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $280M | |
| Total Assets | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Accounts Payable | $39M | $24M | $30M | $25M | $26M | $43M | $38M | $59M | $29M | $26M | · | $26M | $26M | $33M | · | $31M | |
| Current Liabilities | $362M | $371M | $406M | $374M | $336M | $399M | $404M | $394M | $346M | $373M | · | $377M | $340M | $328M | · | $302M | |
| Capital Leases | $166M | $170M | $173M | $176M | $180M | $187M | $191M | $194M | $198M | $201M | · | $191M | $195M | $187M | · | $160M | |
| Other Non-current Liabilities | $123M | $117M | $104M | $113M | $129M | $120M | $109M | $96M | $110M | $101M | · | $62M | $73M | $67M | · | $2M | |
| Total Liabilities | $650M | $658M | $683M | $663M | $645M | $706M | $703M | $685M | $653M | $676M | · | $629M | $615M | $588M | · | $470M | |
| Common Stock | $249.0K | $254.0K | $262.0K | $268.0K | $270.0K | $275.0K | $282.0K | $286.0K | $285.0K | $295.0K | · | $311.0K | $320.0K | $325.0K | · | $323.0K | |
| Paid-in Capital | $2.11B | $2.15B | $2.23B | $2.26B | $2.25B | $2.29B | $2.34B | $2.36B | $2.32B | $2.39B | · | $2.49B | $2.53B | $2.56B | · | $2.51B | |
| Retained Earnings | $-263M | $-216M | $-77M | $-106M | $-220M | $-163M | $-99M | $-90M | $-200M | $-259M | · | $-126M | $11M | $6M | · | $-4M | |
| AOCI | $-2M | $-415.0K | $3M | $4M | $1M | $2M | $-1M | $4M | $-5M | $-5M | · | $-14M | $-14M | $-9M | · | $-18M | |
| Stockholders' Equity | $1.84B | $1.94B | $2.16B | $2.16B | $2.03B | $2.13B | $2.24B | $2.28B | $2.12B | $2.13B | $2.26B | $2.35B | $2.53B | $2.56B | $2.49B | $2.49B | |
| Liabilities + Equity | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Shares Outstanding | 248,885,000 | 253,701,000 | 262,483,000 | 268,098,000 | 270,132,000 | 275,033,000 | 281,732,000 | 285,780,000 | 285,222,000 | 295,032,000 | 302,793,000 | 310,970,000 | 320,253,000 | 324,985,000 | 323,951,000 | 322,541,000 |
Arus Kas 12
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $8M | $7M | $7M | $7M | $10M | $7M | $7M | $6M | $7M | $6M | $6M | $7M | $6M | $6M | |
| Stock-based Comp | $33M | $29M | $45M | $31M | $36M | $26M | $12M | $23M | $25M | $19M | $24M | $40M | $25M | $17M | $26M | $37M | |
| Restructuring | · | · | $-13M | $20M | $0 | $0 | $34M | $96.0K | $475.0K | $33M | · | $0 | $0 | $0 | · | · | |
| Other Non-cash | · | $5M | · | · | · | $19M | · | · | · | $6M | · | · | · | $21M | · | · | |
| Operating Cash Flow | $308M | $252M | $425M | $290M | $49M | $211M | $377M | $271M | $120M | $69M | $11M | $117M | $121M | $84M | $74M | $110M | |
| CapEx | $7M | $2M | $-16M | $1M | $3M | $3M | $1M | $8M | $7M | $10M | $13M | $9M | $6M | $12M | $10M | $43.0K | |
| Investing Cash Flow | $91M | $-51M | $374M | $25M | $248M | $50M | $-28M | $-217M | $82M | $112M | $62M | $35M | $-74M | $-50M | $-246M | $-69M | |
| Stock Repurchased | $323M | $430M | $486M | $104M | $302M | $284M | $311M | $12M | $264M | $185M | $209M | $217M | $124M | $0 | $0 | $0 | |
| Net Stock Activity | · | $-430M | · | · | · | $-284M | · | · | · | $-185M | · | · | · | · | · | · | |
| Financing Cash Flow | $-344M | $-457M | $-529M | $-104M | $-316M | $-295M | $-289M | $6M | $-262M | $-184M | $-206M | $-220M | $-125M | $5M | $-2M | $-2M | |
| Net Change in Cash | $55M | $-256M | $270M | $212M | $-19M | $-34M | $60M | $60M | $-61M | $-3M | $-134M | $-68M | $-78M | $39M | $-174M | $39M | |
| Free Cash Flow | · | $250M | · | · | · | $208M | · | · | · | $59M | · | · | · | $72M | · | · |
Profitabilitas 5
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.5% | 41.1% | · | 39.6% | 37.6% | 33.6% | · | 25.2% | 43.3% | 6.9% | · | -3.7% | 16.6% | 7.0% | · | 20.1% | |
| Net Margin | 33.7% | 34.5% | · | 32.4% | 32.5% | 28.7% | · | 21.9% | 35.5% | 8.8% | · | 0.22% | 17.3% | 9.8% | · | 17.8% | |
| EBITDA Margin | 39.5% | 42.3% | · | 39.6% | 37.6% | 35.0% | · | 25.2% | 43.3% | 8.4% | · | -3.7% | 16.6% | 8.7% | · | 20.1% | |
| ROA | 8.2% | 7.8% | · | 6.7% | 6.8% | 5.7% | · | 4.0% | 7.6% | 1.2% | · | 0.04% | 2.7% | 1.4% | · | 2.7% | |
| ROE | 10.9% | 10.3% | · | 8.7% | 8.9% | 7.5% | · | 5.1% | 9.7% | 1.6% | · | 0.04% | 3.3% | 1.7% | · | 3.2% |
Likuiditas & Solvabilitas 2
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.3 | · | 3.8 | 3.5 | 3.5 | · | 3.9 | 4.3 | 3.5 | · | 3.8 | 4.7 | 5.0 | · | 6.1 | |
| Quick Ratio | 3.2 | 3.0 | · | 3.5 | 3.2 | 3.3 | · | 3.7 | 4.0 | 3.2 | · | 3.6 | 4.4 | 4.7 | · | 5.8 |
Efisiensi 3
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.8 | · | 0.8 | 0.7 | 0.8 | · | 0.7 | 0.6 | 0.5 | · | 0.6 | |
| Receivables Turnover | 2.0 | 2.0 | · | 2.1 | 1.6 | 2.1 | · | 2.1 | 2.0 | 1.8 | · | 2.0 | 2.0 | 1.9 | · | 2.1 |
Valuasi (TTM) 10
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.41B | $2.33B | · | $2.26B | $2.30B | $2.16B | · | $2.07B | $2.00B | $1.78B | · | $1.76B | $1.71B | $1.60B | · | $1.52B | |
| Net Income TTM | $801M | $749M | · | $656M | $689M | $541M | · | $382M | $346M | $160M | · | $195M | $265M | $252M | · | $251M | |
| Market Cap | $13.90B | $11.13B | · | $10.75B | $12.47B | $9.51B | · | $7.42B | $6.41B | $7.00B | · | $6.79B | $6.12B | $6.31B | · | $5.06B | |
| P/E | 18.9 | 16.4 | · | 17.5 | 19.5 | 18.8 | · | 20.1 | 19.7 | 48.4 | · | 36.4 | 23.3 | 24.9 | · | 20.1 | |
| P/S | 5.8 | 4.8 | · | 4.8 | 5.4 | 4.4 | · | 3.6 | 3.2 | 3.9 | · | 3.9 | 3.6 | 4.0 | · | 3.3 | |
| P/B | 7.5 | 5.8 | · | 5.0 | 6.1 | 4.5 | · | 3.3 | 3.0 | 3.3 | · | 2.9 | 2.4 | 2.5 | · | 2.0 | |
| P / Tangible Book | 7.8 | 5.9 | · | 5.1 | 6.3 | 4.6 | · | 3.4 | 3.1 | 3.4 | · | 3.0 | 2.5 | 2.5 | · | 2.1 | |
| P / Cash Flow | · | 44.2 | · | · | · | 45.0 | · | · | · | 101.7 | · | · | · | 74.7 | · | · | |
| P / FCF | · | 44.5 | · | · | · | 45.6 | · | · | · | 118.4 | · | · | · | 87.1 | · | · | |
| Earnings Yield | 5.3% | 6.1% | · | 5.7% | 5.1% | 5.3% | · | 5.0% | 5.1% | 2.1% | · | 2.8% | 4.3% | 4.0% | · | 5.0% |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Margin Operasi % | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% |
| Laba Bersih | $783M | $521M | $208M | $182M | $231M |
| EPS Dilusian | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
Neraca
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Rasio Lancar | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 |
| Rasio Cepat | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 |
Arus Kas
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $876M | $672M | $293M | $335M | $337M |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Sinyal Perdagangan Sinyal beli/jual terbaru dengan harga masuk dan rasio risiko/imbalan
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 811 pengaju · $9.1B total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 135 (+27 vs Kuartal sebelumnya) | 61 (-13 vs Kuartal sebelumnya) | 240 (-1 vs Kuartal sebelumnya) | 274 (+16 vs Kuartal sebelumnya) | +39.8M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $732.794.424 | 13.468.010 | 8,04% | Saham |
| RENAISSANCE TECHNOLOGIES LLC | $730.617.099 | 13.427.993 | 8,01% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $655.266.268 | 12.043.122 | 7,19% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $595.843.747 | 10.950.997 | 6,53% | Saham |
| STATE STREET CORP | $542.471.563 | 9.970.071 | 5,95% | Saham |
| FULLER & THALER ASSET MANAGEMENT, INC. | $485.848.030 | 8.929.389 | 5,33% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $362.702.104 | 6.664.894 | 3,98% | Saham |
| D. E. Shaw & Co., Inc. | $281.389.313 | 5.171.647 | 3,09% | Saham |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $237.550.034 | 4.365.926 | 2,60% | Saham |
| TWO SIGMA INVESTMENTS, LP | $229.058.537 | 4.209.861 | 2,51% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $221.832.835 | 4.077.060 | 2,43% | Saham |
| ASSETMARK, INC | $186.834.364 | 3.433.824 | 2,05% | Saham |
| Stephens Investment Management Group LLC | $147.451.698 | 2.710.011 | 1,62% | Saham |
| NORGES BANK | $146.301.199 | 2.688.866 | 1,60% | Saham |
| FIRST TRUST ADVISORS LP | $138.383.701 | 2.543.353 | 1,52% | Saham |
| Caisse de depot et placement du Quebec | $113.950.809 | 2.094.299 | 1,25% | Saham |
| GOLDMAN SACHS GROUP INC | $106.578.308 | 1.958.800 | 1,17% | Saham |
| AMERICAN CENTURY COMPANIES INC | $97.484.439 | 1.791.664 | 1,07% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $86.563.209 | 1.590.943 | 0,95% | Saham |
| Caligan Partners LP | $84.512.985 | 1.553.262 | 0,93% | Saham |
| MILLENNIUM MANAGEMENT LLC | $66.309.793 | 1.218.706 | 0,73% | Saham |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $63.086.055 | 1.159.457 | 0,69% | Saham |
| BANK OF AMERICA CORP /DE/ | $58.788.318 | 1.080.469 | 0,64% | Saham |
| Robeco Institutional Asset Management B.V. | $56.032.453 | 1.029.819 | 0,61% | Saham |
| ENVESTNET ASSET MANAGEMENT INC | $51.671.488 | 949.669 | 0,57% | Saham |
| FMR LLC | $48.839.667 | 897.623 | 0,54% | Saham |
| Gotham Asset Management, LLC | $48.569.794 | 892.663 | 0,53% | Saham |
| Swedbank AB | $45.801.141 | 841.778 | 0,50% | Saham |
| Allspring Global Investments Holdings, LLC | $44.544.520 | 825.510 | 0,49% | Saham |
| Retirement Systems of Alabama | $44.107.739 | 810.655 | 0,48% | Saham |
| BOOTHBAY FUND MANAGEMENT, LLC | $43.750.809 | 804.095 | 0,48% | Saham |
| RAYMOND JAMES FINANCIAL INC | $41.924.320 | 770.526 | 0,46% | Saham |
| Capital Impact Advisors, LLC | $41.061.268 | 754.664 | 0,45% | Saham |
| BlackRock, Inc. | $40.753.525 | 749.008 | 0,45% | Saham |
| RHUMBLINE ADVISERS | $35.723.294 | 656.559 | 0,39% | Saham |
| CANADA PENSION PLAN INVESTMENT BOARD | $35.464.438 | 651.800 | 0,39% | Saham |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $34.721.830 | 639.680 | 0,38% | Saham |
| MARSHALL WACE, LLP | $34.322.590 | 630.814 | 0,38% | Saham |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $34.315.027 | 630.675 | 0,38% | Saham |
| AMERIPRISE FINANCIAL INC | $32.255.716 | 592.827 | 0,35% | Saham |
| BARCLAYS PLC | $31.502.574 | 578.985 | 0,35% | Saham |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $31.496.480 | 578.873 | 0,35% | Saham |
| Arbejdsmarkedets Tillaegspension | $30.855.911 | 567.100 | 0,34% | Saham |
| Pictet Asset Management Holding SA | $30.153.926 | 555.438 | 0,33% | Saham |
| California Public Employees Retirement System | $29.366.600 | 539.728 | 0,32% | Saham |
| CAPITAL FUND MANAGEMENT S.A. | $28.686.856 | 527.235 | 0,31% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $28.655.734 | 526.663 | 0,31% | Saham |
| JANUS HENDERSON GROUP PLC | $26.675.806 | 621.814 | 0,29% | Saham |
| Woodline Partners LP | $26.411.049 | 485.408 | 0,29% | Saham |
| Driehaus Capital Management LLC | $26.025.500 | 478.322 | 0,29% | Saham |
| EULAV Asset Management | $25.901.500 | 476.043 | 0,28% | Saham |
| Squarepoint Ops LLC | $25.774.398 | 473.707 | 0,28% | Saham |
| Swiss National Bank | $25.648.874 | 471.400 | 0,28% | Saham |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $25.156.355 | 462.348 | 0,28% | Saham |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24.600.555 | 452.133 | 0,27% | Saham |
| IEQ CAPITAL, LLC | $24.580.697 | 451.768 | 0,27% | Saham |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $23.831.580 | 438.000 | 0,26% | Saham |
| Baird Financial Group, Inc. | $23.565.461 | 433.109 | 0,26% | Saham |
| FRANKLIN RESOURCES INC | $23.480.472 | 431.547 | 0,26% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23.347.331 | 429.100 | 0,26% | Opsi beli |
| Assenagon Asset Management S.A. | $23.324.098 | 428.673 | 0,26% | Saham |
| BANK OF NOVA SCOTIA | $22.837.676 | 419.730 | 0,25% | Saham |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $22.615.516 | 415.650 | 0,25% | Saham |
| South Street Advisors LLC | $22.275.019 | 409.392 | 0,24% | Saham |
| Bridgewater Associates, LP | $21.810.738 | 400.859 | 0,24% | Saham |
| VICTORY CAPITAL MANAGEMENT INC | $21.480.143 | 394.783 | 0,24% | Saham |
| ROYAL BANK OF CANADA | $20.031.000 | 368.153 | 0,22% | Saham |
| SEI INVESTMENTS CO | $19.897.640 | 365.698 | 0,22% | Saham |
| LAZARD ASSET MANAGEMENT LLC | $18.664.208 | 343.029 | 0,20% | Saham |
| Nuveen, LLC | $18.299.226 | 336.321 | 0,20% | Saham |
| Nuveen Asset Management, LLC | $18.252.629 | 548.127 | 0,20% | Saham |
| NFJ INVESTMENT GROUP, LLC | $17.880.160 | 328.619 | 0,20% | Saham |
| SAWGRASS ASSET MANAGEMENT LLC | $17.808.447 | 327.301 | 0,20% | Saham |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $17.565.616 | 322.838 | 0,19% | Saham |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $17.472.485 | 407.379 | 0,19% | Saham |
| ING GROEP NV | $16.943.274 | 311.400 | 0,19% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $16.529.758 | 303.800 | 0,18% | Opsi jual |
| Brandywine Global Investment Management, LLC | $16.490.117 | 376.229 | 0,18% | Saham |
| CAPTRUST FINANCIAL ADVISORS | $16.488.532 | 303.042 | 0,18% | Saham |
| INTECH INVESTMENT MANAGEMENT LLC | $16.262.224 | 298.883 | 0,18% | Saham |
| HighTower Advisors, LLC | $15.842.121 | 291.162 | 0,17% | Saham |
| SEIZERT CAPITAL PARTNERS, LLC | $15.411.796 | 283.253 | 0,17% | Saham |
| Trexquant Investment LP | $14.974.122 | 275.209 | 0,16% | Saham |
| Clark Capital Management Group, Inc. | $14.792.882 | 271.878 | 0,16% | Saham |
| ALLIANCEBERNSTEIN L.P. | $14.763.381 | 344.215 | 0,16% | Saham |
| VAN ECK ASSOCIATES CORP | $14.270.709 | 262.281 | 0,16% | Saham |
| GLOBEFLEX CAPITAL L P | $13.874.169 | 254.993 | 0,15% | Saham |
| Sofinnova Investments, Inc. | $13.831.022 | 254.200 | 0,15% | Opsi jual |
| JANE STREET GROUP, LLC | $13.815.570 | 253.916 | 0,15% | Saham |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $13.724.052 | 252.234 | 0,15% | Saham |
| Voleon Capital Management LP | $13.682.047 | 251.462 | 0,15% | Saham |
| BLAIR WILLIAM & CO/IL | $13.233.352 | 243.215 | 0,15% | Saham |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $13.027.000 | 239.418 | 0,14% | Saham |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12.745.021 | 297.156 | 0,14% | Saham |
| MERITAGE PORTFOLIO MANAGEMENT | $12.679.099 | 289.279 | 0,14% | Saham |
| VANGUARD ASSET MANAGEMENT, Ltd | $12.516.694 | 230.044 | 0,14% | Saham |
| Susquehanna Portfolio Strategies, LLC | $12.500.643 | 229.749 | 0,14% | Saham |
| MILLENNIUM MANAGEMENT LLC | $12.035.492 | 221.200 | 0,13% | Opsi beli |
| Illinois Municipal Retirement Fund | $11.750.764 | 215.967 | 0,13% | Saham |
| CWM, LLC | $11.300.486 | 263.476 | 0,12% | Saham |
Orang dalam perusahaan 43 orang dalam · 22 pejabat · 10 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Michael Morrissey | President and CEO | 18 Mei 2026 G | 2.004.327 | 0 | 0 | $0 |
| Christopher J. Senner | EVP and CFO | 18 Mei 2026 S | 952.317 | 0 | 3 | $-4.556.048 |
| Deborah Burke | SVP & Chief Financial Officer | 15 Nov. 2014 M | 18.156 | 0 | 0 | $0 |
| Frank Karbe | EVP and CFO | 15 Feb. 2014 M | 93.990 | 0 | 0 | $0 |
| Kristine M Ball | Controller & Interim CFO | 10 Des. 2003 A | 4.913 | 0 | 0 | $0 |
| Patrick J. Haley | EVP, Commercial | 20 Mei 2026 S | 357.638 | 0 | 7 | $-7.597.268 |
| Brenda Hefti | SVP and General Counsel | 18 Mei 2026 S | 106.762 | 0 | 2 | $-1.154.264 |
| Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | 16 Mei 2025 M | 465.393 | 0 | 0 | $0 |
| Jeffrey Hessekiel | EVP & General Counsel | 15 Mei 2025 S | 693.396 | 0 | 0 | $0 |
| Vicki L Goodman | EVP, Prod Dev & Med Aff &CMO | 3 April 2023 A | 307.654 | 0 | 0 | $0 |
| Peter Lamb | EVP, Scientific Strategy & CSO | 15 Des. 2022 M | 410.958 | 0 | 0 | $0 |
| Gisela Schwab | Pres, Prod Dev & Med Aff & CMO | 26 Juli 2021 M | 689.078 | 0 | 0 | $0 |
| Pamela A Simonton | EVP and General Counsel | 15 Nov. 2013 M | 17.139 | 0 | 0 | $0 |
| Lupe M Rivera | EVP, Operations | 15 Agu 2011 M | 19.219 | 0 | 0 | $0 |
| Frances K Heller | EVP, Business Development | 15 Mei 2011 M | 17.125 | 0 | 0 | $0 |
| Ian D Malcolm | VP, STRATEGIC MARKETING | 8 Des. 2006 A | — | 0 | 0 | $0 |
| Christoph Pereira | VP, Legal Affairs & Secretary | 8 Des. 2006 A | — | 0 | 0 | $0 |
| Jeffrey Latts | Executive VP, Development | 8 Des. 2006 A | — | 0 | 0 | $0 |
| Gregory Plowman | Sr VP, CSO | 13 Des. 2004 A | — | 0 | 0 | $0 |
| Steven P James | Sr VP, Commercial Ops | 10 Des. 2003 A | — | 0 | 0 | $0 |
| Jane M Green | VP, Corp Communications | 10 Des. 2003 A | — | 0 | 0 | $0 |
| Geoffrey M Duyk | Pres R&D & CSO | 4 Nov. 2003 S | 941.355 | 0 | 0 | $0 |
| Alan M Garber | Direktur | 21 Maret 2024 M | 35.703 | 0 | 0 | $0 |
| Jacqueline Wright | Direktur | 1 Juni 2023 A | 51.756 | 0 | 0 | $0 |
| Carl B Feldbaum | Direktur | 9 Feb. 2023 M | 18.701 | 0 | 0 | $0 |
| Lance Willsey | Direktur | 26 Mei 2022 A | 424.415 | 0 | 0 | $0 |
| Vincent T Marchesi | Direktur | 26 Mei 2022 A | 93.989 | 0 | 0 | $0 |
| Charles Cohen | Direktur | 6 Juli 2021 M | 261.375 | 0 | 0 | $0 |
| George A Scangos | Direktur | 18 Mei 2020 S | 714.717 | 0 | 0 | $0 |
| FORMELA JEAN FRANCOIS | Direktur | 7 Sep. 2005 S | 584.519 | 0 | 0 | $0 |
| Mary C Beckerle | — | 10 Agu 2026 S | 16.079 | 0 | 4 | $-1.932.572 |
| Sue Gail Eckhardt | — | 1 Juni 2026 S | 16.079 | 0 | 2 | $-660.828 |
| Jack L Wyszomierski | — | 1 Juni 2026 S | 284.384 | 0 | 2 | $-4.580.661 |
| Tomas J. Heyman | — | 27 Mei 2026 A | 50.649 | 0 | 0 | $0 |
| Bob Oliver | — | 27 Mei 2026 A | 29.487 | 0 | 2 | $-1.325.340 |
| Julie Smith | — | 27 Mei 2026 A | 28.957 | 0 | 3 | $-4.687.346 |
| Maria C Freire | — | 27 Mei 2026 A | 109.186 | 0 | 1 | $-949.164 |
| Stelios Papadopoulos | — | 27 Mei 2026 A | 1.197.595 | 0 | 1 | $-4.355.000 |
| George Poste | — | 27 Mei 2026 A | 127.199 | 0 | 1 | $-2.742.600 |
| Dana Aftab | — | 26 Mei 2026 S | 594.741 | 0 | 4 | $-7.701.255 |
| Frank Mccormick | — | 6 Des. 2013 A | — | 0 | 0 | $0 |
| Scott J. Garland | — | 18 Sep. 2013 A | — | 0 | 0 | $0 |
| Jason S Fisherman | — | 8 Sep. 2005 S | 7.881 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 4 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Roberts, Jr., Thomas G., Saito Edric C., Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. | 14 Agu 2026 | 5,60% | Amandemen | — | SEC |
| Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Fried, Richard B, Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Patel, Rajiv A., Roberts, Jr., Thomas G., Saito Edric C., Seybold, William, Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. ×8 pengajuan | 5 Jan. 2026 | 5,90% | Amandemen | — | SEC |
| Caligan Partners LP, David Johnson ×3 pengajuan | 2 Juni 2023 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan | 29 Nov. 2001 | — | Pengajuan awal | M&A / penjualan | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 152 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| IDNA · iShares Trust | 3,47% | 131.275 SH | 8 Agu 2026 | Harian |
| SAWG · ETF Series Solutions | 2,82% | 1.599 NS | 30 April 2026 | N-PORT |
| CANC · Tema ETF Trust | 2,78% | 96.885 NS | 31 Mei 2026 | N-PORT |
| XMHQ · Invesco Exchange-Traded Fund Trust | 2,67% | 2.774.135 SH | 8 Agu 2026 | Harian |
| PBE · Invesco Exchange-Traded Fund Trust | 2,59% | 173.519 SH | 8 Agu 2026 | Harian |
| MCOW · Pacer Funds Trust | 2,38% | 528 NS | 30 April 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 2,24% | 441.186 NS | 30 April 2026 | N-PORT |
| LYLD · Cambria ETF Trust | 2,01% | 2.722 NS | 30 April 2026 | N-PORT |
| AZTD · Tidal Trust I | 1,92% | 18.950 NS | 30 April 2026 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1,84% | 172.947 SH | 8 Agu 2026 | Harian |
| BBP · ETFis Series Trust I | 1,74% | 23.148 NS | 30 April 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 1,61% | 1.596 NS | 30 April 2026 | N-PORT |
| BUL · Pacer Funds Trust | 1,45% | 41.520 NS | 30 April 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,39% | 306.870 NS | 30 April 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,36% | 5.563 NS | 30 April 2026 | N-PORT |
| RFG · Invesco Exchange-Traded Fund Trust | 1,30% | 86.397 SH | 8 Agu 2026 | Harian |
| PTH · Invesco Exchange-Traded Fund Trust | 1,29% | 58.887 SH | 8 Agu 2026 | Harian |
| COWG · Pacer Funds Trust | 1,26% | 616.432 NS | 30 April 2026 | N-PORT |
| TAX · EA Series Trust | 1,13% | 5.692 NS | 29 Mei 2026 | N-PORT |
| CALF · Pacer Funds Trust | 1,07% | 829.382 NS | 30 April 2026 | N-PORT |
| AFMC · First Trust Exchange-Traded Fund VI… | 1,03% | 32.938 NS | 31 Mei 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 1,00% | 116.281 NS | 30 April 2026 | N-PORT |
| IBB · iShares Trust | 0,98% | 1.788.613 SH | 8 Agu 2026 | Harian |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,93% | 13.681 SH | 8 Agu 2026 | Harian |
| AGNG · Global X Funds | 0,92% | 14.988 NS | 31 Mei 2026 | N-PORT |
| OASC · Unified Series Trust | 0,91% | 15.171 NS | 31 Mei 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,90% | 25.550 NS | 30 April 2026 | N-PORT |
| FLOW · Global X Funds | 0,90% | 5.093 NS | 31 Mei 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0,88% | 16.470 NS | 30 April 2026 | N-PORT |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,72% | 248.016 SH | 8 Agu 2026 | Harian |
| FLRG · FIDELITY COVINGTON TRUST | 0,72% | 45.672 NS | 30 April 2026 | N-PORT |
| IJK · iShares Trust | 0,70% | 1.469.020 SH | 8 Agu 2026 | Harian |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,69% | 7.149 NS | 31 Mei 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,68% | 82.717 NS | 31 Mei 2026 | N-PORT |
| BIB · ProShares Trust | 0,66% | 9.600 NS | 31 Mei 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,64% | 4.091 NS | 31 Mei 2026 | N-PORT |
| VUSE · ETF Series Solutions | 0,63% | 85.930 NS | 31 Mei 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,60% | 2.080 NS | 30 April 2026 | N-PORT |
| PDP · Invesco Exchange-Traded Fund Trust | 0,59% | 165.207 SH | 8 Agu 2026 | Harian |
| QGRO · AMERICAN CENTURY ETF TRUST | 0,58% | 255.026 NS | 31 Mei 2026 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,53% | 19.762 NS | 31 Mei 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 0,51% | 502 NS | 30 April 2026 | N-PORT |
| VFQY · VANGUARD WELLINGTON FUND | 0,49% | 42.746 SH | 8 Agu 2026 | Harian |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,48% | 64.828 NS | 30 April 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,47% | 5.095 NS | 30 April 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,45% | 147.282 SH | 8 Agu 2026 | Harian |
| IQSM · New York Life Investments ETF Trust | 0,44% | 30.864 NS | 30 April 2026 | N-PORT |
| XJH · iShares Trust | 0,41% | 33.981 SH | 8 Agu 2026 | Harian |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,41% | 47.960 NS | 30 April 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,41% | 33.169 SH | 8 Agu 2026 | Harian |